Entering text into the input field will update the search result below

Illumina up 15% premarket on launch single-cell gene sequencer

Jan. 10, 2017 8:55 AM ETIllumina, Inc. (ILMN) StockBy: Douglas W. House, SA News Editor3 Comments
  • Illumina (NASDAQ:ILMN) is up 15% premarket on increased volume in response to the debut of the Illumina Bio-Rad Single-Cell Sequencing Solution, enabling single-cell genetic analysis. As the name implies, the company developed the product with Bio-Rad (BIO).
  • Clive Svendsen, Ph.D., Director, Cedars-Sinai Board of Governors Regenerative Medicine Institute in Los Angeles says, "Single-cell genomics provides the opportunity to look at stem cells turning into neurons that are lost in diseases like Parkinson's and amyotrophic lateral sclerosis with much higher accuracy."
  • Cedars-Sinai Project Scientist Ritchie Ho, Ph.D., adds, "Using the solution made it possible to detect single cells in a population that was maturing much faster than others, allowing us to produce better models of disease."
  • Product shipments will commence in early February.
  • #JPM17

Recommended For You

About ILMN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ILMN--
Illumina, Inc.